trial

Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial

NCTId NCT06456983
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 140 (estimated)
Sponsored by Central Institute of Mental Health, Mannheim
Primary completion 2027-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
140 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2025-02-14
Primary completion
2027-07
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Central Institute of Mental Health, MannheimLead Sponsor

Investigators

1
Alexander Sartorius, ProfPrincipal Investigator

Sites

14 total
Aachen, GermanyAugsburg, GermanyGöppingen, GermanyGöttingen, GermanyHanover, GermanyHeidelberg, GermanyIngolstadt, GermanyMainz, GermanyMannheim, GermanyMünchen, GermanySaarbrücken, GermanySiegen, Germany

Facts & assertions

4 sourced
Enrollment
140
Phase
NA
Primary Completion Date
2027-07
Status
RECRUITING
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Central Institute of Mental Health, Mannheim
company
indication
Schizophrenia
indication
Treatment Resistant Schizophrenia
indication
Schizophrenia, Treatment-Resistant
indication
investigator
Alexander Sartorius, Prof
person